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Abstract
C-6 Esterifications of delpheline (1) were carried out to provide 20 new diterpenoid alkaloid
derivatives (4–22, 24). Three natural alkaloids (1–3) and all synthesized compounds (4–25) were
evaluated for cytotoxic activity against lung (A549), prostate (DU145), nasopharyngeal (KB), and
vincristine-resistant nasopharyngeal (KB-VIN) cancer cell lines and interestingly, showed an
improved drug resistance profile compared to paclitaxel. Particularly, 6-(4-fluoro-3-
methylbenzoyl)delpheline (22) displayed 2.6-fold greater potency against KB-VIN cells compared
with the parental non-drug resistant KB cells. 6-Acylation of 1 appears to be critical for producing
cytotoxic activity in this alkaloid class and a means to provide promising new leads for further
development into antitumor agents.
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Natural products have been the major sources of currently available anticancer drugs.
According to a review of New Chemical Entities (NCE) from 1981 to 2006, approximately
73% of anticancer drugs were not purely synthetic compounds, with 47% being natural
products, directly derived from natural products, or mimicking natural products in one form
or another.1 Diterpenoid alkaloids have been isolated from the genera Aconitum, Consolida
and Delphinium of the Ranunculaceae family, and the genus Spiraea of the Rosaceae family.
Diterpenoid alkaloids are classified according to their chemical structure as C18-diterpenoid
alkaloids, which have either a lappaconitine or a ranaconitine skeleton, C19-diterpenoid
alkaloids, which have either an aconitine, lycoctonine, lactone-type, pyro-type, rearranged-
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type, or 7,17-seco-type skeleton, and C20-diterpenoid alkaloids, which have either an
arcutine, atisine, denudatine, hetidine, hetisine, kusnezoline, napelline, racemulosine,
tricalysiamide, or vakognavine skeleton.2–4 The pharmacological properties of aconitine-
type C19-diterpenoid alkaloids, including aconitine, hypaconitine, jesaconitine, and
mesaconitine, have been studied extensively and reviewed.5,6 Two reports on the effects of
C19-diterpenoid alkaloids on cancer cells have appeared in recent years. 8-O-Azeloyl-14-
benzoylaconine, an aconitine-type C19-diterpenoid alkaloid, exhibited antiproliferative
activity,7 and the cytotoxic effects of various C19-diterpenoid alkaloids against tumor cell
lines were reported.8 Our previous study demonstrated the effects of various naturally
occurring and semi-synthetic C19- and C20-diterpenoid alkaloids on growth of the A172
human malignant glioma cell line.9 Antitumor properties and radiation-sensitizing effects of
various types of novel derivatives prepared from C19- and C20-diterpenoid alkaloids were
also investigated.10 Two novel hetisine-type C20-diterpenoid derivatives showed significant
suppressive effects against the Raji non-Hodgkin’s lymphoma cell line.11 In addition, the
effects of various semi-synthetic novel hetisine-type C20-diterpenoid alkaloids on the growth
of the A549 human lung cancer cell line were examined and subsequent structure-activity
relationships for the anti-proliferative effects against A549 cells were considered.12
However, little information is available regarding the cytotoxic properties of lycoctonine-
type C19-diterpenoid alkaloids and their chemically transformed products. Herein, we report
our study results on the unique cytotoxic activities of delpheline (1), a lycoctonine-type C19-
diterpenoid alkaloid, and its derivatives.
Delpheline (1), pacinine (2) and yunnadelphinine (3) were purified from the seeds of
Delphinium elatum cv. Pacific Giant by a previously described procedure.13,14 Delpheline
(1) was reacted with various acyl chlorides at 80°C in pyridine to give C-6 substituted
benzoyl and cinnamoyl derivatives (4–22). Delpheline (1) and 6-(3-
trifluoromethylbenzoyl)delpheline (12) were hydrolyzed under acidic conditions to provide
the 7,8-demethylene derivatives, 7,8-demethylenedelpheline (23)15 and 7,8-demethylene-6-
(3-trifluoromethylbenzoyl)delpheline (24), respectively. Oxidation of delpheline (1) with
KMnO4–acetone gave 19-oxodelpheline (25).
The three natural alkaloids (1–3) and all synthesized compounds (4–25) were evaluated for
cytotoxic activity against four human tumor cell lines [lung carcinoma (A549), prostate
carcinoma (DU145), nasopharyngeal (KB) and multi-drug resistant variant expressing P-
glycoprotein (KB-VIN)]. Paclitaxel was used as a positive control (data shown in Table I).
Interestingly, the natural alkaloids (1–3) and synthetic analogs that did not contain a C-6
ester group (23, 25) were inactive (EC50 > 20 µM). Thus, acylation of the C-6 hydroxy
group of 1 was necessary for cytotoxic activity. The methylenedioxy group of a lycoctonine-
type C19-diterpenoid alkaloid might also be necessary for an inhibitory effect against A549,
DU145, KB and KB-VIN cell lines, as compound 24 lost activity against all cell lines
compared with the related compound 12.
Among the C-6 esterified compounds, 4 [6-(4-chlorobenzoyl)delpheline], 20 [6-(4-
benzyloxybenzoyl)delpheline], and 21 [6-(3-fluoro-4-trifluoromethylbenzoyl)delpheline]
exhibited the highest average potency over all cell lines (average EC50 9.83, 9.57, and 9.41
µM, respectively). However, compound 16 [6-(3-trifluoromethylcinnamoyl)delpheline]
showed significantly increased cytotoxic activity (EC50 10.2 µM) against A549 cells
compared with 4, 20, and 21, but was generally less potent against DU145, KB, and KB-
VIN cells. Compounds 7, 11, 14, and 17 were inactive against all four cancer cell lines,
while 5, 6, 8–10, 13, and 18 showed very limited potency.
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The most striking observations from the data in Table 1 were the degree and relative ratio of
KB/KB-VIN potency. Among the four cancer cell lines tested, the highest potency was
found against the KB-VIN cell line by compounds 20–22 (EC50 4.22, 4.40, and 4.71 µM,
respectively), followed by compounds 19, 15, 4, 16, and 12 (EC50 6.50, 6.80, 8.27, 9.10, and
11.9 µM, respectively). Generally, all of the active compounds showed the highest potency
against the KB-VIN cell line compared with the other three cancer cell lines tested.
Moreover, compounds 4, 12, 20, and 21 displayed similar potency against the KB and KB-
VIN cell lines (ratio of EC50 KB / EC50 KB-VIN: 1.07, 1.25, 1.60, and 1.24, respectively).
Even more notably, compounds 15, 19, 16, and 22 showed over twofold selectivity between
the two cell lines, with highest cytotoxic activity against the KB-VIN cell line (ratio of EC50
KB / EC50 KB-VIN: 2.15, 2.28, 2.31, and 2.57, respectively).
The identity of the substituent on the C-6 acyl group affected the cytotoxic potency. For
instance, the compounds with the highest potency against the KB-VIN cell line contained
chloro (4), fluoro (15, 21, 22), trifluoromethyl (12, 16, 21), ethoxy (19), or benzyloxy (20)
substituents on the acyl group. Against the KB-VIN cell line, compounds 21 and 22 with
both fluoro and trifluoromethyl/methyl groups were more potent than 12 with only a single
trifluoromethyl group and even more potent than 5 with a single fluoro group. Similarly,
compound 16 [6-(3-trifluoromethylcinnamoyl)delpheline] showed increased cytotoxic
activity against most cell lines compared with the related fluorinated compounds 17 [6-(4-
fluorocinnamoyl)delpheline] and 18 [6-(6-trifluoromethylnicotinoyl)delpheline]. Moreover,
compounds with nitro, methoxy, phenyl, trifluoromethoxy, trifluoromethythio, and methyl
carboxylate groups on a C-6 benzoate ester were generally less potent.
In conclusion, we have synthesized various C-6 acylated derivatives of 1, a lycoctonine-type
C19-diterpenoid alkaloid. All derivatives were screened against four tumor cell lines, and the
C-6 acylated was found to be critical for cytotoxic activity. Compounds 4, 12, 20, and 21
displayed the greatest potency over all four tested cell lines. While these four compounds
showed comparable potency against both KB and KB-VIN cancer cell lines, some
compounds showed tumor-selective activity. Compounds 15, 16, 19, and 22 exhibited
greater inhibitory activity against drug-resistant KB-VIN cells (2.15–2.57 fold) than the
parental KB cells. Continued studies are merited to further develop these promising new
leads as antitumor agents, particularly with enhanced tumor selectivity.
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Table 1
Cytotoxic activity data for diterpenoid alkaloid and derivatives [ED50 (µM)] a,b
A549 DU145 KB KB-VIN
1 >20 >20 >20 >20
2 >20 >20 >20 >20
3 >20 >20 >20 >20
4 14.8 ± 3.76 7.40 ± 1.16 8.85 ± 2.02 8.27 ± 1.62
5 >20 15.6 ± 5.39 >20 15.0 ± 6.51
6 >20 17.2 ± 3.26 >20 17.7 ± 3.51
7 >20 >20 >20 >20
8 >20 17.1 ± 11.4 >20 17.4 ± 7.42
9 18.7 ± 6.57 20.3 ± 7.06 20.1 ± 7.63 18.9 ± 4.95
10 >20 16.6 ± 12.7 >20 17.9 ± 4.16
11 >20 >20 >20 >20
12 >20 12.6 ± 2.96 14.9 ± 4.93 11.9 ± 3.26
13 >20 >20 19.1 ± 4.78 20.3 ± 2.66
14 >20 >20 >20 >20
15 19.9 ± 10.1 16.9 ± 6.74 14.6 ± 7.05 6.80 ± 4.99
16 10.2 ± 2.62 15.1 ± 5.97 >20 9.10 ± 1.51
17 >20 >20 >20 >20
18 >20 >20 >20 18.7 ± 5.17
19 20.0 ± 0.89 15.6 ± 2.56 14.8 ± 3.27 6.50 ± 2.16
20 14.1 ± 2.93 13.2 ± 5.68 6.76 ± 1.74 4.22 ± 1.09
21 16.5 ± 2.24 11.3 ± 7.9 5.44 ± 1.75 4.40 ± 0.83
22 >20 19.8 ± 4.58 12.1 ± 7.83 4.71 ± 1.44
23 >20 >20 >20 >20
24 >20 >20 >20 >20
25 >20 >20 >20 >20
Paclitaxel 0.0064 ± 0.0013 0.0059 ± 0.0019 0.0060 ± 0.0008 0.76 ± 0.22
a
Cytotoxicity as EC50 values for each cell line, the concentration of compound that caused 50% reducation in absorbance at 515 nm relative to
untreated cells using sulforhodamine B assay.
b
Lung carcinoma (A549), prostate carcinoma (DU145), nasopharyngeal (KB) and multi-drug resistant variant expressing P-glycoprotein (KB-
VIN).
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